会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Assay procedures
    • 测定程序
    • US4804625A
    • 1989-02-14
    • US656011
    • 1984-09-27
    • Larry E. MorrisonGarfield P. RoyerMichael J. Heller
    • Larry E. MorrisonGarfield P. RoyerMichael J. Heller
    • G01N33/536C12Q1/28C12Q1/37C12Q1/42G01N33/535G01N33/543G01N33/563
    • G01N33/535Y10S435/81Y10S436/805
    • Binding assay methods involving determining the presence of analytes in samples through enzymatic formation of detectable substances in amounts related to the amount of analyte present in the sample and monitoring for the presence of the substances in distinct phases. Methods according to the invention include use of labelled materials which associate with the analyte to be determined or compete with the analyte for association with an added binder. The labelled materials employed include label portions which enzymatically form substances from substrates provided in or existing as a first phase, or, upon enzymatic treatment in a first phase, disassociate into substances capable of existing in or as a second distinct phase. Formation of the detectable substances is monitored by determining the transfer of the substance to a second distinct phase in contact with the first phase or by determining formation of a second distinct phase. The assays are useful in determining human IgG protein in blood samples and other constituents of blood or other biological samples without elaborate instrumentation, allowing for practice outside the clinical laboratory.
    • 结合测定方法包括通过以与样品中存在的分析物的量相关的量的酶形成可检测物质来测定样品中分析物的存在并监测不同阶段中物质的存在。 根据本发明的方法包括使用与待测定的分析物相关联的标记材料或与分析物竞争与所添加的粘合剂缔合。 所使用的标记材料包括标记部分,其从在第一阶段中提供或存在的底物酶促形成物质,或者在第一阶段的酶处理中,分解成能够存在于或作为第二不同相的物质。 通过确定物质与第一相接触的第二不同相的转移或通过确定第二不同相的形成来监测可检测物质的形成。 该测定法可用于测定血液样本中血液或其他生物样品中其他成分的人类IgG蛋白质,而无需精心设计,可在临床实验室外进行实践。